ArticleProceedings of the National Academy of Sciences of the United States of America2021
Tissue-restricted control of established central nervous system autoimmunity by TNF receptor 2-expressing Treg cells.
Open access · greenAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 49 citations in OpenAlex.
- Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity.Cancer research · 2026Article
- Soluble tumor necrosis factor receptors in diabetes: risk sensing and receptor-resolved targeting.Endocrine journal · 2026Review
- Promising TNF-α inhibitors: Targeting pathogenic TNF-α/TNFR signaling to restore Th17/Treg balance in rheumatoid arthritis.Journal of pharmaceutical analysis · 2026Review
- Defining nature, responses and drivers of regulatory- and conventional CD4Frontiers in immunology · 2026Article
- Decoding Treg diversity and dysfunction to advance Treg-based therapies in autoimmune and inflammatory diseases.Frontiers in immunology · 2026Review
- Treg Susceptibility to Cladribine-Induced Depletion Correlates With Therapy Response in Patients With Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2026Article
- Two subsets of regulatory CD8iScience · 2025Article
- Functional and dysfunctional T regulatory cell states in human tissues in RA and other autoimmune arthritic diseases.bioRxiv : the preprint server for biology · 2025Article
- Peripheral nerve-targeting and pain-promoting transcriptomic signatures in early Guillain-Barré syndrome.bioRxiv : the preprint server for biology · 2025Article
- TNF Production or TNFR2 Expression Characterize Distinct States of Regulatory T Cells that Cooperate in Treg Expansion in Cancer and Chronic Inflammation.European journal of immunology · 2025Article
- TNFR2 Agonism: Basic Science and Promising Treatment for Multiple Sclerosis and Related Diseases.International journal of molecular sciences · 2025Review
- Treatment Options for the Comorbidity of Multiple Sclerosis with Other Chronic Inflammatory Diseases.Deutsches Arzteblatt international · 2025Review
- Single intracerebroventricular TNFR2 agonist injection impacts remyelination in the cuprizone model.Journal of molecular medicine (Berlin, Germany) · 2025Article
- Nonlinear Dynamics of TNFR1 and TNFR2 Expression on Immune Cells: Genetic and Age-Related Aspects of Inflamm-Aging Mechanisms.Biomedicines · 2025Article
- Chemokines as therapeutic targets for multiple sclerosis: a spatial and chronological perspective.Frontiers in immunology · 2025Review
- Targeting cytokine networks in neuroinflammatory diseases.Nature reviews. Drug discovery · 2024Review
- Jagged-1+ skin Tregs modulate cutaneous wound healing.Scientific reports · 2024Article
- Tregs from human blood differentiate into nonlymphoid tissue-resident effector cells upon TNFR2 costimulation.JCI insight · 2024Article
- TNF and TNF receptors as therapeutic targets for rheumatic diseases and beyond.Nature reviews. Rheumatology · 2023Review
- Sequential treatment with a TNFR2 agonist and a TNFR1 antagonist improves outcomes in a humanized mouse model for MS.Journal of neuroinflammation · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 2 countries.
Emilie RoninSorbonne Université, INSERM, CNRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI)-Paris, F-75013 Paris, France.ORCID 0000-0003-0295-7933
Charlotte PouchySorbonne Université, INSERM, CNRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI)-Paris, F-75013 Paris, France.
Maryam KhosraviSorbonne Université, INSERM, CNRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI)-Paris, F-75013 Paris, France.
Morgane HilaireSorbonne Université, INSERM, CNRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI)-Paris, F-75013 Paris, France.ORCID 0000-0003-4562-5998
Sylvie GrégoireSorbonne Université, INSERM, CNRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI)-Paris, F-75013 Paris, France.
Armanda CasrougeSorbonne Université, INSERM, CNRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI)-Paris, F-75013 Paris, France.ORCID 0000-0002-7356-0901
Sahar KassemSorbonne Université, INSERM, CNRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI)-Paris, F-75013 Paris, France.
David SleursSorbonne Université, INSERM, CNRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI)-Paris, F-75013 Paris, France.
Gaëlle H MartinSorbonne Université, INSERM, CNRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI)-Paris, F-75013 Paris, France.ORCID 0000-0001-8849-9413
Noémie ChansonSorbonne Université, INSERM, CNRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI)-Paris, F-75013 Paris, France.
Yannis LombardiSorbonne Université, INSERM, CNRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI)-Paris, F-75013 Paris, France.
Guilhem LalleCentre de Recherche en Cancérologie de Lyon, Labex DEVweCAN, INSERM, CNRS, Université Claude Bernard Lyon 1, Centre Léon Bérard, 69008 Lyon, France.ORCID 0000-0002-8861-9523
Harald WajantDivision of Molecular Internal Medicine, Department of Internal Medicine II, University Hospital Würzburg, 97070 Würzburg, Germany.ORCID 0000-0002-2005-3949
Cédric AuffrayInstitut Cochin, CNRS, INSERM, Paris Université, F-75014 Paris, France.
Bruno LucasInstitut Cochin, CNRS, INSERM, Paris Université, F-75014 Paris, France.
Gilles MarodonSorbonne Université, INSERM, CNRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI)-Paris, F-75013 Paris, France.ORCID 0000-0003-4889-6785
Yenkel Grinberg-BleyerCentre de Recherche en Cancérologie de Lyon, Labex DEVweCAN, INSERM, CNRS, Université Claude Bernard Lyon 1, Centre Léon Bérard, 69008 Lyon, France; yenkel.grinberg-bleyer@inserm.fr benoit.salomon@inserm.fr.ORCID 0000-0002-3515-8305
Benoît L SalomonSorbonne Université, INSERM, CNRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI)-Paris, F-75013 Paris, France; yenkel.grinberg-bleyer@inserm.fr benoit.salomon@inserm.fr.ORCID 0000-0001-9673-5578
Centre National de la Recherche Scientifique · FRUniversité Claude Bernard Lyon 1 · FRUniversitätsklinikum Würzburg · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD4
Indexed as
AnimalsBone MarrowCentral Nervous SystemCTLA-4 AntigenEncephalomyelitis, Autoimmune, ExperimentalHumansMiceMice, KnockoutMultiple SclerosisPositive Regulatory Domain I-Binding Factor 1Receptors, Tumor Necrosis Factor, Type IISignal TransductionT-Lymphocytes, RegulatoryCTLA-4 AntigenCtla4 protein, mousePositive Regulatory Domain I-Binding Factor 1Prdm1 protein, mouseReceptors, Tumor Necrosis Factor, Type IITnfrsf1b protein, mouseautoimmune diseasesTNFTreg cells
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.